Efficacy of Sucroferric Oxyhydroxide in Dialysis

The percentage of the 530 patients who underwent analysis reached target serum phosphorus levels more than twice a year after beginning SO therapy. This increased from 17.7% at baseline to 24.5%, 30.5%, 36.4%, and 36.0% at Q1 through Q4 (P <.0001 for all). Regardless of the baseline phosphate binder, decreases in serum phosphorus were seen at all follow-up time periods (P <.0001). During SO therapy, patients’ average daily pill burden decreased by 50% (P <.0001). Compared to a mean baseline of 8.5 tablets. After switching to SO, there was a significant improvement in phosphorus-attuned albumin and protein consumption (P <.0001). For patients who were women, Hispanic/Latino patients, and black/African-American patients, among other predefined categories, SO’s efficacy was constant.

Hemodialysis patients who switched to sucroferric oxyhydroxide had a two-fold increased chance of reaching target. ,Phosphorus levels with a reduction of the daily pill burden associated with phosphate binder. Increased nutritional status is suggested by improvements in phosphorus-sensitive albumin and protein intake.
In 2019, Ketteler and colleagues investigated the Long-Term Impact of Phosphate. Binders on Mineral and Bone Disorder Indices in Dialysis Patients Suffering from Hyperphosphatemia in Chronic Kidney Disease. Their subsequent publication in Nephrology Dialysis Transplantation was titled. “Effects of sucroferric oxyhydroxide  and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients.” Efficacy of Sucroferric Oxyhydroxide in Dialysis

Significant and long-lasting 30% decreases in serum phosphorus were observed with both the sucroferric oxyhydroxide and sevelamer treatments (P < 0.001). Over the course of a year, there was a significant 64% drop in median intact fibroblast growth factor-23 (FGF-23) (P < 0.001). After 24 weeks, intact parathyroid hormone dropped dramatically (P < 0.001), but by Week 52, it had nearly restored to baseline levels. There were not much changes in the serum calcium levels. Tarrate-resistant acid phosphatase 5b (TRAP5b) was the bone resorption marker that showed the greatest drop (P < 0.001), although CTx showed a brief increase before reaching baseline levels by Week 52. Over the course of a year of treatment, the bone-specific alkaline phosphatase and osteocalcin indicators increased.APA